



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: ZHENG <i>et al.</i> Appl. No.: 10/560,075 Filed: December 9, 2005 For: Antineoplastic Agents Targeted Via GLUT Transporters	Confirmation No.: 9659 Art Unit: 1609 Examiner: Bland, Layla D. Atty. Docket: 1694.0580004/JMC/CMB
--	---

Reply to Restriction Requirement

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

In reply to the Office Action dated March 13, 2007, requesting an election of one invention to prosecute in the above-referenced patent application, Applicant hereby provisionally elects to prosecute the invention of Group I, represented by claims 1-12 and 25. The Office also requested an election of species. Applicant hereby provisionally elects to prosecute photodynamic therapy agents and specifically BChlPP, listed in claim 9. This election is made without prejudice to or disclaimer of the other claims or inventions disclosed. It is believed that claims 1, 2, 4-6, 9, 10, 13, 25-27, 31 and 32 read on the elected species.

This election is made with traverse.

The above-identified application is a National Phase Entry Under 35 U.S.C. § 371 and, as such, PCT Rule 13 requiring unity of invention applies. Title 37 of the Code of Federal Regulations states:

(b) An international or a national stage application containing claims to different categories of invention will be considered to have unity of